11 Result(s)
within
Michael E. Wechsler
-
Article
Leukotriene Modifiers and Churg-Strauss Syndrome
Zafirlukast, montelukast and pranlukast are all cysteinyl leukotriene receptor antagonists that have recently been approved for the treatment of asthma. Within 6 months of zafirlukast being made available on t...
-
Article
The Placebo Effect in Asthma
The placebo effect is a complex phenomenon occurring across a variety of clinical conditions. While much placebo research has been conducted in diseases defined by self-report such as depression, chronic pain,...
-
Article
Open AccessLTC4 synthase polymorphism modifies efficacy of botanical seed oil combination in asthma
Botanical seed oils reduce the generation of leukotrienes in patients with asthma.
-
Article
Open AccessBacterial biogeography of adult airways in atopic asthma
Perturbations to the composition and function of bronchial bacterial communities appear to contribute to the pathophysiology of asthma. Unraveling the nature and mechanisms of these complex associations will r...
-
Article
Open AccessGenetic associations of the response to inhaled corticosteroids in asthma: a systematic review
There is wide variability in the response to inhaled corticosteroids (ICS) in asthma. While some of this heterogeneity of response is due to adherence and environmental causes, genetic variation also influence...
-
Article
Open AccessPharmacogenetic investigation of efficacy response to mepolizumab in eosinophilic granulomatosis with polyangiitis
Treatment of patients with the rare disease eosinophilic granulomatosis with polyangiitis (EGPA) with mepolizumab, a monoclonal antibody to interleukin-5 (IL-5) that reduces blood eosinophil counts, as an add-...
-
Article
Open AccessInternational severe asthma registry (ISAR): protocol for a global registry
Severe asthma exerts a disproportionately heavy burden on patients and health care. Due to the heterogeneity of the severe asthma population, many patients need to be evaluated to understand the clinical featu...
-
Article
Open AccessType 2 and interferon inflammation regulate SARS-CoV-2 entry factor expression in the airway epithelium
Coronavirus disease 2019 (COVID-19) is caused by SARS-CoV-2, an emerging virus that utilizes host proteins ACE2 and TMPRSS2 as entry factors. Understanding the factors affecting the pattern and levels of expre...
-
Article
Open AccessSOURCE: a phase 3, multicentre, randomized, double-blind, placebo-controlled, parallel group trial to evaluate the efficacy and safety of tezepelumab in reducing oral corticosteroid use in adults with oral corticosteroid dependent asthma
Many patients with severe asthma continue to experience asthma symptoms and exacerbations despite standard-of-care treatment. A substantial proportion of these patients require long-term treatment with oral co...
-
Article
Open AccessUnmet need in severe, uncontrolled asthma: can anti-TSLP therapy with tezepelumab provide a valuable new treatment option?
Despite treatment with standard-of-care medications, including currently available biologic therapies, many patients with severe asthma have uncontrolled disease, which is associated with a high risk of hospit...
-
Article
Open AccessEfficacy of Tezepelumab in Patients with Severe, Uncontrolled Asthma Across Multiple Clinically Relevant Subgroups in the NAVIGATOR Study
Many patients with severe asthma continue to experience symptoms and exacerbations despite treatment with standard-of-care therapy. In the phase 3 NAVIGATOR study, tezepelumab significantly reduced exacerbatio...
